Vineti, Inc., a San Francisco, CA-based software automation and analytics platform for cell and gene therapies has raised $33.5 million in Series B funding led by Canaan and DFJ, with participation from GE Ventures, Section 32, Casdin Capital, and LifeForce Capital, along with other undisclosed investors. The funding round will further advance the first cloud-based “platform of record” specifically built to move transformative new personalized therapies such as CAR-T cell therapy into mainstream medicine. In addition, the funding will also support Vineti’s further expansion in Europe and Asia-Pacific, providing a global solution to a critical personalized medicine barrier.
Vineti’s configurable, cloud-based software platform improves cell and gene therapy product performance, promotes regulatory compliance, and enables faster, safer, broader access for patients. The platform automates, orchestrates, and simplifies the complex workflows behind personalized therapies, and helps pharmaceutical partners address emerging opportunities and challenges as these therapies move into mainstream medicine. The Vineti platform also enables seamless integrations with other parts of the therapy ecosystem. Vineti is currently serving patients, healthcare providers, and researchers in a large, growing, global healthcare network.
n 2017, the first two CAR-T cell therapies from Novartis and Kite, a Gilead company, were approved by the U.S. Food and Drug Administration (FDA) and launched, underscoring the rapid growth in the field of cell and gene therapy. As a result of a commercial agreement, Vineti helped Kite reach its approval milestone by providing critical cloud-based infrastructure to help support commercial access to Kite’s Yescarta™ therapy.
For all its pharmaceutical partners, Vineti’s platform provides critical capabilities, including comprehensive and consistent Chain of Custody and Chain of Identify – two required processes vital to the traceability, transparency, security, and safety of the entire personalized therapy process. Vineti supports a range of cell and gene therapy innovators, including pharmaceutical partners not yet publicly announced.
The recent FDA approval activity marks the beginning of a wave of new therapies with the potential to transform the treatment of cancer and serious genetic disorders. By late 2017, there were 946 cell and gene therapy clinical trials underway worldwide, with more than 53 percent of those in oncology[1]. In 2018, oncology is expected to remain the largest market in medicine and is projected to grow to $165 billion by 2021[2].
With Vineti, caregivers, suppliers, and pharmaceutical pioneers are empowered to reach more patients sooner by partnering their products and therapies with a digital, data-driven platform focused on personalized patient-based medical products, scalability, efficiency and safety. In addition to its work with its pharmaceutical partners, the company continues its close collaboration with healthcare providers, regulators, and leading researchers.
